Contravir Pharmaceuticals Inc. reported that 10 hepatitis B patients treated with its once-daily tenofovir prodrug, CMX157 (tenofovir exalidex), saw viral load reductions comparable to those achieved with Viread, an earlier tenofovir prodrug from Gilead Sciences Inc.